Purpose To evaluate the tolerance and efficacy of front-line docetaxel plus gemcitabine treatment in patients with inoperable pancreatic cancer
Introduction
There is no curative treatment for unresectable or metastatic pancreatic cancer and survival is approximately 6 months [1] . Gemcitabine is active against various tumours [2] , and has resulted in 11% objective responses [3, 4] and a significant clinical benefit in chemotherapynaive [5] and 5-Fluorouracil-refractory [6] patients with pancreatic cancer.
In preclinical studies docetaxel has been very active against munne pancreatic ductal carcinomas [7, 8] . In a phase II study, docetaxel produced 6% objective responses, 58% stable disease and a median overall survival of 36 weeks in 33 patients with inoperable pancreatic cancer [9] In addition, the performance status and pain were improved in 24% and 67% of assessable patients respectively, whilst 29% experienced weight gain [9] .
Based on these observations and our previous experience with the combination in metastatic breast cancer [10] , a multicenter phase II study was conducted to evaluate the efficacy and toxicity of the docetaxelgemcitabine combination in patients with locally advanced and metastatic pancreatic cancer
Patients and methods

Patient population
Patients aged 18-75 years with histologically confirmed pancreatic adenocarcinoma and bidimensionally measurable or evaluable disease, who had not received prior chemotherapy or radiotherapy, were enrolled Other eligibility criteria were WHO performance status (PS) 0-2, life expectancy of at least three months, absence of biliary obstruction, absolute granulocyte count > 1500/dl. platelet count > 120,000/dl, serum creatine < I 2 mg/dl and bilirubin < 1 5 mg/dl, no pre-existing heart disease, no CNS involvement Patients with infection, malnutrition or a second primary were excluded from ihe study All patients gave written informed consent Treatment Gemcitabine (Gemzar, Elli-Lilly, Indianapolis, Indiana) was given on days I and 8 at 1000 mg/m 2 in 250 ml saline i v for 30-min Docetaxel (Taxotere, Rhone-Poulenc Rorer. Collegeville. Pennsylvania) was administered after standard premedicalion on day 8 at 100 mg/m 2 in 250 ml saline i v for one-hour Cycles were repeated every 21 days All patients received rh-G-CSF (Granocyte, Rhone-Poulenc Rorer) 150 ug/m 2 subcutaneously on days 9-15 Patients with objective response or stable disease were treated until progression The protocol was approved by the Ethical and Scientific Committees of the participating hospitals
The docetaxel and gemcitabine (d8) doses were reduced by 25% in febrile or grade 4 neutropenia or thrombocytopenia lasting more than five days and by 15% in grade 3 neutropenia and/or thrombocytopenia A one-week treatment delay and a 20% dose reduction was performed in patients with grade 4 asthenia or grade 2-4 neurotoxicity Toxicities were graded according to the WHO criteria
Response evaluation
All patients were assessed for response by ultrasound and/or computed tomography after three cycles according to the WHO response criteria Responses were confirmed by two independent radiologists
Assessment of clinical benefit
Pain relief was based on analgesics consumption (narcotics and nonnarcotics) and the patient's own evaluation of pain using a scale of 0 (no pain) to 10 (maximum pain) A more than 50% decrease or increase in analgesics consumption and pain intensity was characterized as pain improvement or deterioration, respectively Vomiting and diarrhea were assessed according to the daily number of episodes and fatigue and unorexia using a scale of 0-10 A 50% decrease or increase in episodes or symptom intensity was characterized as 'improvement' or 'deterioration', respectively An increase or decrease in body weight of more than 2 kg during treatment was defined as'weight gain'or 'weight loss'
Results
From June 1997 to November 1998, 54 patients were enrolled. Their characteristics are shown in Table 1 . Forty (74%) patients had pain at the time of enrollment; 10 (18.5%) were taking opioids whilst 30 (55.5%) nonsteroid analgesics.
Compliance with treatment
A total of 216 cycles was administered with a median of 3 cycles/patient (range 1-9) and the median interval between cycles was 21 days (range 21-32) The median delivered dose-intensity for docetaxel and gemcitabine was 27.5 mg/m 2 /week (range 15-33) and 627.5 mg/m 2 / week (range 383-667) corresponding to 83% and 94% of the protocol dose, respectively. Forty-three (20%) cycles were delayed due to: grade 3-4 neutropenia or/and thrombocytopenia (13 cycles), asthenia (5 cycles), elevated transaminases (2 cycles), grade 3 diarrhea (1 cycle), non-neutropenic infection (5 cycles) and due to patients' request for irrelevant reasons (17 cycles). Two patients received only one cycle because of personal reasons (one patient) and grade 4 neutropenia and diarrhea with sepsis resulting in death (one patient). Dose reductions were required in 30 (14%) cycles due to hematological (19 cycles) and non-hematological (11 cycles) toxicity.
Response to treatment
Partial responses occurred in seven (13%) patients (95% confidence interval (CI)-4.0%-21 9%), stable disease in 18 (33%) and progressive disease in 29 (54%) (intent-totreat). The median duration of response was 24 weeks (range 8-50) and time to tumour progression 32 weeks (range 14-62). The median overall survival was 26 weeks (range 4-88), and the probability for 1-year survival was 30% The median survival of patients with stage III-IV (39) 14 (26) 20 (37) 20 (37) 8 (15) 8 (15) 38 (70) 51 (94) 19 (35) 7(13) 31(57) 4(7) 13 (24) 15 (28) 20 (37) 19 (35) 14 (26) 40(74) 40 (74) 36 (66) 33 (61) 36 (66) disease was 24 weeks (range 4-88), and for inoperable stage II disease 60 weeks (range 4-72) (P = 0.038).
Pain improvement occurred after a median of 2 cycles (range 1-4) in 43% of patients. Six often patients using opioid analgesics before treatment could discontinue them, and two others reduced intake by > 50% for two to five months. Among 30 patients using non-steroid analgesics, 8 stopped (for 2-4 months) whilst four reduced their use > 50%. Weight gain, apetite and asthenia were improved in 12 (33%), 9 (27%) and 6 (16%) patients, respectively. Performance status was improved in 17 (33%) patients. A more than 50% reduction in CA 19.9 serum levels was observed in 12 (41%) of 29 patients with elevated pre-treatment levels Toxicity Table 2 demonstrates the toxicity profile of the regimen. Six (11%) patients developed febrile neutropenia with a median duration of hospitahzation of four days One patient died of septic shock in the ICU.
Discussion
The results of this study demonstrate that the combination of docetaxel-gemcitabine has moderate activity in patients with advanced pancreatic cancer. In another study the docetaxel-gemcitabine combination resulted in one partial response among 18 patients with advanced pancreatic cancer and a median survival of 5.4 months [11] . Moreover, gemcitabine with protracted intravenous infusion of 5-FU resulted in 19.2% objective responses, 45% improvement of disease-related symptoms and 10 3 months median survival in patients with advanced pancreatic cancer [12] . The survival achieved by the docetaxel-gemcitabine regimen is comparable with that of single-agent docetaxel or gemcitabine [4, 6, 9] . In our study a clinical benefit was demonstrated with an improvement of performance status, pain, weight gain and anorexia in 33%, 43%, 33% and 27% of patients, respectively Although a possible contribution by the co-administration of steroids for docetaxel premedication cannot be excluded, improvement of performance status and tumor-related symptoms were exclusively observed in patients achieving PR and/or SD. The docetaxel-gemcitabine combination had an acceptable toxicity profile.
In conclusion, the docetaxel-gemcitabine combination with rh-G-CSF support is an outpatient regimen which confers a clinical benefit in a substantial proportion of patients with pancreatic cancer. However, given its high cost, it cannot be recommended since single agent gemcitabine or docetaxel seem to produce similar results.
